Pfizer Inc announced that the first participants have been dosed in a pivotal Phase 3 clinical trial to evaluate the efficacy, safety, tolerability and immunogenicity of the company’s quadrivalent modified RNA (modRNA) influenza vaccine candidate in approximately 25,000 healthy U.S. adults.
- Read more about Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/pfizer-initiates-phase-3-study-of-mrna-based-influenza-vaccine
No comments:
Post a Comment